BREAKER-101 trial - Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors

“First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumor”

Sponsor TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Study Start: October 2024

No locations listed

TRIAL LINK: NCT06625775

https://clinicaltrials.gov/study/NCT06625775?term=NCT06625775&rank=1

NOTE: All interventional trials involve risk. 

So please consult with your oncology team as well as ask questions of the trial researchers.

RAS Initiative update: Taking our drugs to the clinic

July 2024

Slides 13 – 23- The Role of RAS-PI 3’ kinase in cancer

https://deainfo.nci.nih.gov/advisory/fac/0724/McCormick.pdf?fbclid=IwY2xjawFv5J9leHRuA2FlbQIxMAABHX-QA3UoP3NFvMcRVDY7-_JkNcu-hyWv5rDa1WDSDXqD28bOmvlpmz6rUA_aem_4zAiVSsxU5wxhdSLwy1eFw

San Antonio Breast Cancer Conference – December 2023

Mini Oral Abstracts – Pedro J. Beltran, PhD

video presentation starts at 7 minutes

https://www.youtube.com/watch?v=qPzp_JaSq4Y

San Antonio Breast Cancer Conference

Slides from Bridge Bio scientific presentations

https://bridgebiooncology.com/wp-content/uploads/BB010203-SABCS23-Branded-Final.pdf?fbclid=IwY2xjawFv5kNleHRuA2FlbQIxMAABHXsig_fp6UAwSGo3Q6XgTlWnseTUU4knqelDLZ9fbTmE1ga1eH1qQd5cvA_aem_bIEFKqoA8yyycwpeZutjEw